BIOCYTOGEN
21.6.2024 12:51:24 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.
RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite® and RenLite® KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.
In addition to the RenLite® platform, Biocytogen’s independently developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse platforms cater to the diverse R&D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice® platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated RenMice® licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice® platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.
The U.S. patent authorization for the RenLite® platform technology demonstrates Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides the United States, patent applications for the RenLite® platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia, and other countries and regions with authorizations in progress.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Value Group Brings Its Integrated Global IROPS Management Model to the World Aviation Festival8.10.2026 08:32:00 CEST | Press release
Value Group, a leading provider of integrated aviation disruption management solutions, returns to the World Aviation Festival as a Gold Sponsor, reinforcing its role in the evolution of airline disruption management. From 13 to 15 October at FIL in Lisbon, the event is one of the aviation industry’s leading international technology conferences and exhibitions, bringing together airlines, airports and travel technology companies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007885823/en/ Thomas Sergnese, Co-CEO & Chief Commercial Officer and Daniele Bocchieri, Co-CEO & Chief Operating Officer At stand 1-180, Value Group will showcase the evolution of its integrated disruption management model and the RUBIK digital ecosystem, demonstrating how technology, operations and governance can work together as one connected system to manage irregular operations more effectively at both global and local level. Over the p
Colruyt Group Crosses the 150 Store Milestone With Rollout of Toshiba ELERA® Self Service Store Deployments8.10.2026 07:30:00 CEST | Press release
Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium Toshiba Global Commerce Solutions today announced the successful deployment of its ELERA® Self Service solution across 144 Colruyt Group stores: Okay, Okay City, Spar Colruyt Group and Bio-Planet. Today, 454 self-checkout systems have already been installed year-to-date across 150 stores. The project continues to expand, with an additional 51 stores planned in 2026 and further rollout in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007465701/en/ Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium. The deployment was designed to support a fast, intuitive, and customer-friendly checkout experience, while maintaining the personal interaction that remains important within the convenience retail environment. Across the
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older8.10.2026 07:00:00 CEST | Press release
New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1 Additional long-term data further demonstrate Nemluvio’s consistent safety profile and sustained efficacy, including improvements in skin clearance, itch, sleep and quality of life in adults with prurigo nodularis up to 148 weeks, and people with atopic dermatitis aged 12 and older up to 152 weeks2,3 Phase II pediatric data will also be presented, with nemolizumab driving meaningful and sustained improvements in children aged 2-11 years with moderate-to-severe atopic dermatitis4 Alongside a product theatre exploring how targeted IL-31 treatment may impact patient outcomes, these findings reinforce Galderma's leadership in advancing treatment goals in atopic dermatitis and prurigo nodularis Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new da
Fuji Electric Joins Helical Fusion as Strategic Investor and Official Partner as Series B Second Close Raises JPY 3.23 Billion8.10.2026 02:00:00 CEST | Press release
Major Japanese industrial players join Helical Fusion as construction of Helix HARUKA advances through a public-private partnership spanning government, national research infrastructure, and Japan’s manufacturing sector Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator with the goal of achieving commercially viable fusion power in the 2030s, today announced the completion of a JPY 3.23 billion (approximately USD 20.6 million) Series B second close. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007813917/en/ Helical Fusion and new investors for the Series B 2nd close The round marks another expansion of the industrial coalition forming around Helical Fusion’s Helix Program. Fuji Electric Co., Ltd., one of Japan’s major electrical and industrial equipment manufacturers, has joined Helical Fusion as both an investor and an Official Partner of the Helix Program. Other new investors in the sec
New INRIX Parking Scorecard Reveals Cities with the Most Parking, Highest Prices, and Lowest Availability7.10.2026 22:16:00 CEST | Press release
The Scorecard analyzes more than 120 downtown areas across North America and Europe, comparing parking availability, prices and curb use policies INRIX, a leader in transportation analytics and mobility intelligence, today released its first-ever INRIX Parking Scorecard, the largest comparative analyses of downtown parking conditions across North America and Europe. Drawing on parking availability, curb regulations, pricing data and parking infrastructure from more than 120 downtown areas in 14 countries, the report reveals significant differences in parking conditions and how cities allocate curb space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007322796/en/ New INRIX Parking Scorecard: Where Downtown Parking Costs Most The Scorecard examines parking availability: the probability of finding a parking space alongside on-street and off-street parking pricing, and curb use policies. The findings show that parking condi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom